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For decades, lipid droplets have been considered as the main cellular organelles involved in the fat storage, because of their lipid
composition. However, in recent years, some new and totally unexpected roles have been discovered for them: (i) they are active
sites for synthesis and storage of inflammatory mediators, and (ii) they are key players in cancer cells and tissues, especially in
cancer stem cells. In this review, we summarize the main concepts related to the lipid droplet structure and function and their
involvement in inflammatory and cancer processes.
1. Introduction
Lipid droplets (LDs) have been considered for a long time as
the fat storage compartment in cellular metabolic processes,
and only recently have they drawn an increased attention by
the scientific community. A quick search in the Web of Sci-
ence database using any of the following search strings “lipid
droplets,” “lipid bodies,” “adiposomes,” or “oil bodies” [1]
yields more than 85,000 articles (Figure 1), almost all of them
published in the last 20 years. In fact, LDs are now considered
as dynamic and functional organelles not only responsible for
fat storage but also involved in membrane biosynthesis, lipid
metabolism, cell signaling, inflammation, and cancer [2–4].
In this review, we present an initial overview of LDs,
indicating their lipid and protein composition and the major
models of LD biogenesis. Then, we focus on the role of LDs in
cancer and their presence in cancer stem cells (CSCs),
highlighting a potential link between LDs and cancer stem-
ness. In this regard, Raman spectroscopy can provide a new
and powerful tool for the investigation and characterization
of LDs in different living cellular systems.
The review does not address individual lipid signaling
pathways and their interplay with glucose metabolism in
cancer and other diseases, which can be found elsewhere.
2. LD Composition and Biogenesis
LDs are spherical organelles with size ranging from a few
dozens of nanometers to hundreds of micrometers depend-
ing on cell type in which they are found. Depending on the
tissue of origin, they contain variable ratios of neutral lipids,
such as cholesteryl esters (CEs), retinyl esters, and triglycer-
ides (TAGs) with saturated or unsaturated chains. Further,
they are surrounded by a single layer of phospholipids, with
phosphatidylcholine as the most abundant component, and
various kinds of proteins [5–7]. Differences in size and
amount of LDs, as well as in their lipid/protein composition,
may reflect not only differences among cell types (intercellu-
larly) but also differences between cellular metabolic states of
a single cell type (intracellularly). In addition, in vitro LDs
are also dependent on the culture conditions, while in vivo
LDs are influenced by resting, fasting, or pathological status.
Hindawi
Stem Cells International
Volume 2017, Article ID 1656053, 17 pages
https://doi.org/10.1155/2017/1656053
LDs are found in almost all human cells, particularly in
hepatocytes, enterocytes, and adipocytes [7].
Evidence shows that some protein components, present
on LD surface, are derived from endoplasmic reticulum
(ER) [8, 9]; in fact, the enzymes involved in TAG and CE
synthesis reside on the ER membrane.
Ultrastructural analysis of LDs shows that they are often
found in intimate contact with both the (i) mitochondria,
where the β-oxidation of fatty acids takes place, and with
(ii) ER cisternae, suggesting a strong relationship between
these organelles [10] (Figure 2).
Based on the prevailing budding model for LD formation,
newly synthesized neutral lipids accumulate inside the ER
membrane bilayers, from which the cytoplasmic leaflet buds
off taking phospholipids and ER membrane proteins. Lipids
are channeled into this nascent LD, which is initially tethered
to ER. The new LD is then released into the cytosol [11]. It
has been proposed that Arf1/COPI complexes may trigger
the formation of bridges between the ER and the nascent
LD [12]. In an alternative model, neutral lipids accumulate
inside the ER bilayer, forming an oil lens, which is subse-
quently excised [13]. Once released into the cytoplasm, LDs
tend to increase their volume either by localized lipid syn-
thesis [9], transport of lipids to LDs [14], or by fusion with
other LDs (Figure 2) [15, 16].
Furthermore, while LDs are generally considered to be
located in the cell cytoplasm, very recently, Ohsaki et al.
[17] have convincingly demonstrated the presence of LDs
inside the nuclei of several human and mammalian cell lines
by using confocal and electron microscopy. The authors also
investigated the molecular basis for nuclear LD formation. In
light of these considerations, the suggested model of LDs as
unique subcellular domains (niches) proposed by Welte [4]
offers several intriguing hints.
3. LD Synthesis and Catabolism
Due to the potential toxicity of fatty acids (FA) to cells,
surpluses of nonesterified FAs and cholesterol (CH) are
stored within the LDs as neutral inert molecules, such as
TAGs or sterol esters. The TAGs are made of three FA chains
bound to a glycerol backbone. TAGs are synthesized by a
complex pathway (Figure 2), which initially requires the
following: (i) the activation of saturated and/or unsaturated
FAs to fatty acyl-coenzyme A (FA-CoA) esters by an acyl-
CoA synthetase (ACS) activity and (ii) the phosphorylation
of glycerol by glycerol kinase (GLYK), which is found in
the liver, or the cytosolic synthesis of glycerol-3-phosphate
from dihydroxyacetone phosphate (DHAP) produced during
glycolysis by glycerol-3-phosphate dehydrogenase (GPDH)
enzyme, which mainly occurs in the liver and adipose tissues.
In the adipose tissue and, at lesser extent, in other tissues,
glycerol-3-phosphate is also derived from peroxisomal con-
version of the DHAP in a pathway involving a first acylation
catalyzed by the dihydroxyacetone phosphate acyltransferase
(DHAPAT), followed by a reduction by 1-acyl-dihydroxyac-
etone phosphate oxidoreductase (DHAP-OR) [18].
Once formed, FA-CoA is used for the first acylation of
glycerol-3-phosphate via glycerol-3-phosphate acyltransferase
(GPAT) enzymes, which produces 1-acylglycerol-3-phosphate
(MAG-P) (Figure 2). Then, 1-acyl-glycerol-3-phosphate acyl-
transferase (AGPAT) catalyzes the second acylation convert-
ing MAG-P in 1,2-diacylglycerol phosphate (phosphatidic
acid (PA-P)), which in turn is dephosphorylated to 1,2-
diacylglycerol (DAG) by phosphatidic acid phosphatase
(PAP or lipin). PAP is a cytosolic Mg2+-dependent enzyme
able to transiently localize to the ER membrane for cata-
lyzing the phosphatase reaction [19, 20]. Lastly, acyl-CoA:
diacylglycerol acyltransferase 1 and 2 (DGAT1 and DGAT2)
enzymes catalyze the third esterification of DAG into TAG
(Figure 2) [19].
Another major component of LDs is represented by
CE, which derives from the esterification reaction between
FA-CoA and CH performed by acyl-CoA:cholesterol acyl-
transferase 1 and 2 (ACAT1 and ACAT2). ACAT1 is
expressed in all tissues, while ACAT2 is mainly present
in the intestine and liver [21]. CH is used for membrane
synthesis and repair and, in steroidogenic cells, as a precursor
for steroid hormone synthesis [22].
Newly synthesized TAGs and CEs are then stored in LDs
or, in the liver, secreted in the blood in the form of very-low-
density lipoproteins (VLDL) to be delivered to other tissues.
On the other hand, TAGs can be mobilized from within
LDs to produce energy (Figure 2). This can occur through
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Figure 1: Growth of Web of Science-indexed publications, by year, using the key words “lipid droplets,” “lipid bodies,” “adiposomes,” or
“oil bodies,” from 1950 to 2016.
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two different processes: via degradation by cytoplasmic tri-
glyceride lipases (CTLs) recruited to the LDs, such as adipose
tissue triacylglycerol lipase (ATGL) and hormone-sensitive
lipase (HSL), or by lysosomal lipase following autophagic
pathways. In the former, ATGL bound on LD surface hydro-
lyzes TAGs to DAGs, and HSL, after translocation from cyto-
sol to LDs, converts DAGs into 1-acylglycerols (MAGs), and
finally monoacylglycerol lipase (MGL) hydrolyzes MAGs
into free FAs (FFAs) and glycerol. FFAs may be delivered
to the mitochondria for the β-oxidation, in order to obtain
energy, or used as substrates for reesterification, for mem-
brane synthesis, or as signaling molecules [20, 23]. In the
latter, LDs are incorporated in autophagosomes, which fuse
with lysosomes forming autolysosomes, in a process named
“lipophagy” [24]. Lipophagy is supposed to be the principal
mechanism of LD catabolism in hepatocytes, where ATGL
and HSL are less expressed. Lysosomes contain the lysosomal
acid lipase (LAL) that hydrolyzes TAGs and CEs and prote-
ases that degrade proteins, but the biochemical processes
and molecular mechanisms underlying are poorly known
(Figure 2) [4, 7, 20].
4. Protein Composition of LDs
The proteins associated with LDs coat the surface of mem-
brane monolayer and participate in LD formation, growth,
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Figure 2: Schematic overview of the metabolic pathways required for the de novo synthesis of triacylglycerols and their lipolysis. Simplified
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acid phosphatase; PUFA: polyunsaturated FA; SCDs: stearoyl-CoA desaturases; TAG: triacylglycerol; TCA: tricarboxylic acid cycle.
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trafficking, and catabolism. Different proteins have been
identified by proteomic analysis, mostly classified into three
groups: (1) structural proteins, such as the members of
the PAT (perilipin-ADRP-TIP47) family and the cell
death-inducing DFF45-like effector (CIDE) family; (2)
membrane-trafficking proteins, including but not limited
to Rab10, Rab18, Rab32, and Arf1 proteins and soluble
NSF attachment protein receptors (SNAREs); and (3)
enzymes implicated in lipid synthesis, such as DGAT2,
and catabolism, such as ATGL and HSL [8, 25].
LD-associated proteins can be cytosol-derived proteins
or ER-derived proteins [26]. Their regulation is finely con-
trolled and responds to physiological conditions, like fasting
and feeding and hormones. Further, their expression varies
depending on cell and tissue types. Different PLIN combina-
tions on the LD surface would confer LD tissue specificity
[27, 28]. Interestingly, Hsieh et al. showed that LD composi-
tion and localization can vary at a single cell level. In partic-
ular, FA-enriched LDs localize preferentially to the cell
periphery, while CE-enriched LDs to central regions. Besides,
in various cell types, different exogenous lipid stimuli exert
differential effects on perilipin coating and differential tar-
geting of perilipins to different classes of LDs [29].
The PAT family includes five members: perilipin 1
(PLIN1) [30], perilipin 2 (PLIN2/ADRP/adipophilin) [6],
perilipin 3 (PLIN3/TIP47) [31], perilipin 4 (PLIN4/S3–12)
[32], and perilipin 5 (PLIN5/OXPAT) [33, 34]. It can be also
distinguished in constitutively LD-localized proteins (PLIN1
and PLIN2) or exchangeable LD-localized proteins following
lipogenic or lipolytic stimuli (TIP47, S3-12, and OXPAT)
(Figure 3) [35].
PLIN1 represents the most abundant structural protein
on the LDs and is highly and stably expressed in mature
adipocytes of white and brown adipose tissue and at lesser
levels in macrophages [34, 36, 37].
A recent study showed that the lack of PLIN1 correlates
with the attenuation of the nuclear SREBP-1 expression,
finally resulting in decreased LD formation [38]. The pro-
posed acting mechanism is the control of the interaction/
accessibility of internal stored lipids and external cytosolic
lipases that results in the regulation of lipolysis. In fact, under
basal conditions, PLIN1 hinders the relocation of cytosolic
lipase HSL to LDs and blocks ATGL activity by binding
with the cofactor perilipin-associated comparative gene
identification-58 (CGI-58) requested for ATGL activation
(Figure 3) [39]. On the other hand, under conditions of
energy requirements, the active protein kinase A (PKA)
phosphorylates PLIN1 and HSL, fostering translocation and
binding of HSL on the LD surface [40, 41]. In addition,
CGI-58 is released, which activates ATGL and localizes it to
the LDs, thus stimulating TGA lipolysis [40, 41] (Figure 3).
These observations point out to an important role played
by PLIN1 in LD formation and TGA metabolism [37].
PLIN2 is a ubiquitous mainly associated LD protein,
particularly abundant in the liver [42], whose expression is
positively correlated with TAG levels and LD formation
[43]. During adipogenic differentiation of 3T3-L1 preadipo-
cytes, PLIN2 is replaced by PLIN1 [44]. It has been suggested
that, by hampering the association of ATGL with LDs, PLIN2
hinders lipolytic pathways, which results in increased TAG
levels and in the accumulation of LDs (Figure 3) [45–47].
Similarly to PLIN 2, PLIN3 is also distributed in many
tissues, but, unlike PLIN1 and PLIN2, it localizes to the
cytosol [31, 48, 49]. In the presence of a FA surplus, it
translocates from cytoplasm to nascent LDs stimulating
TAG biosynthesis and storage (Figure 3). This was sug-
gested by the knockdown of PLIN3 in THP-1 cells, in
which TAG level decreased, while they accumulated in
the presence of full-length PLIN3 [50]. Additionally, it dis-
plays apolipoprotein-like properties, the ability to bind to
DAG-rich ER membrane sites during LD formation and
to LDs during TGA mobilization [51, 52].
PLIN4 is selectively expressed in adipocytes and to a
lesser degree in the skeletal and cardiac muscles [53, 54]. Like
PLIN1, PLIN4 appears in the last stages of the adipocyte
differentiation, but differently, it is localized in the cytosol
under basal conditions. In the presence of adipogenic stimuli,
PLIN4 coats nascent LDs together with PLIN3 and PLIN2
[37, 54] and it seems to preferentially target CE-enriched
LDs [29].
PLIN5 expression is specific for oxidizing tissues, such as
heart, liver, and brown adipose tissue, and recently, it has
been also discovered in hepatic and pancreatic cells [55,
56]. It is a cytosolic perilipin able to translocate to LDs fol-
lowing lipogenic stimulation, and PLIN5-associated LDs are
also found in close proximity with mitochondria (where the
FA β-oxidation occurs) in muscle cells [57]. Studies of the
hearts of PLIN5 knockout mice and of mouse hearts overex-
pressing PLIN5 are consistent with a PLIN5 protective role of
LD storages against lipase activity and presumptively against
the toxicity induced by excessive FA oxidation [58, 59].
Altogether, these observations suggest that PLIN1,
PLIN2, and PLIN5 could regulate lipid metabolism by
interacting with lipolytic enzymes or, more probably, by
impairing the access of lipases to LDs, while PLIN3 and
PLIN4 would be involved in the control of the intracellular
neutral lipid packaging and trafficking [54].
The CIDE is another important family of LD coat
proteins, including CIDEA [60], CIDEB, and CIDEC (or
FSP27). CIDEA and CIDEB have been shown to reside on
LDs and on the ER of brown adipose tissue and in the liver,
respectively, while CIDEC in white and brown adipose tis-
sues, but not in normal liver tissues [61]. Recent findings
reveal that CIDE proteins are localized at the contact site
between different LDs, where they probably mediate lipid
transfer, LD fusion, and growth [62, 63]. It has been pro-
posed that the interaction between FSP27 and PLIN1 would
assist FA exchange through a channeling pore between LDs
and would be crucial to protect from lipotoxicity through
the accumulation of TAGs and the formation of large
LDs [30, 64].
Among membrane-trafficking proteins, a variety of
GTPase of the Rab family, Arf1, and SNARE proteins, as well
as caveolins and cavins, have been also described to target to
LDs [1, 6, 65–68]. These proteins seem to be entailed in
trafficking and sequestration of proteins to LDs and in lipid
mobilization from LDs with the aim at delivering them to
different cellular compartments, at regulating their levels,
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and/or at hampering their binding with target partners
[69, 70]. In this context, Rab GTPases are the most abundant
class of proteins associated to LDs, even though, only for
some of them, such as Rab1, Rab5, Rab10, Rab18, and
Rab32, a functional interaction with LDs has been reported
[68, 71]. Recent evidence also suggests a crucial role of
SNARE proteins in the fusion of LDs and of Arf1/COP-I
complex, which would allow ATGL to target LDs by inducing
the dissociation of PLIN2 (Figure 3) [25, 68].
Finally, concerning the enzymatic proteins involved in
lipogenesis and lipolysis, ATGL and HSL are the most
studied members of the lipase family activated under lipo-
lytic stimuli. In particular, HSL is a cytosolic enzyme,
while ATGL is a LD-associated protein [72]. As mentioned
before, after the activation by the PKA phosphorylation,
HSL translocates from cytosol to LDs where it is responsible
for the hydrolysis of DAGs into MAGs (Figure 3) [20, 41].
ATGL accessibility to TGA stored inside LDs appears
mediate by Arf1/COPI complex, which would transport
ATGL to LDs from the ER [12]. Moreover, a recent finding
showed that Golgi brefeldin A resistance factor 1 (GBF1),
an exchange/activator factor of Arf1, also intervenes in the
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translocation of ATGL from ER membrane to LD surface
[73], though the mechanisms underlying are still poorly
understood. Additionally, cofactor CGI-58 and the peptide
G0G1 switch protein 2 (G0S2) appear to be important
elements in the activation of ATGL or in its inhibition,
respectively, as well as in the ATGL transfer from ER to
LDs (Figure 3) [39, 74].
Finally, DGAT enzymes, especially DGAT2, would be
present on LDs to recycle hydrolyzed lipids and expanding
their core under FA surplus [75].
Therefore, LD-associated proteins are linked to both LD
formation and interplay with other cytoplasmic organelles
through complex pathways and, to date, the mechanisms
involved in targeting and recruitment of the proteins from
cytosol and ER onto LD surface, as well as the protein-
specific contribution to LD homeostasis, remain to be
elucidated. For a more exhaustive description of LD-
associated proteins, we refer the readers to more detailed
reviews [26, 71, 76].
5. Lipid Droplets and Cancer
While LD’s responsibility in obesity and related diseases has
been extensively investigated [1], only in recent years has
their implication in cancer attracted the interest of scientists.
As far back as 1963, Aboumrad et al. described a class of
mammary carcinoma characterized by a high number of
stainable lipid vesicles in the cytoplasm [77]. Since that
time, the aforementioned lipid particles were considered
as a not specific degenerative change related to that neo-
plasm. In 1973, Ramos et al. clinically and morphologically
characterized 13 patients with lipid-containing mammary
carcinoma and categorized these tumors as a distinctive
clinic-pathologic variety with a more aggressive behavior
[78]. Since then, lipid-rich carcinoma continued to be
reported in human and animal studies [79, 80]. Nevertheless,
the roles of lipids in cancer development were not clearly
understood and a widely accepted classification of lipid-rich
tumors as a clinically distinctive form of carcinoma was
lacking [81].
Nowadays, there is a general consensus that cancer cells
display metabolic reprogramming compared to healthy cells,
related not only to mechanisms of ATP synthesis through
glycolysis (Warburg effect) [82] but also to de novo lipid
synthesis, with fatty acid synthase (FASN) and sterol regula-
tory element-binding protein (SREBP) family as key players
in many human cancers [83–89]. Under physiological
conditions, normal cells tend to maintain lipid levels under
control, by regulating uptake, synthesis, and mobilization
from internal storages. By contrast, tumor cells are able to
uptake larger amount of lipids, as well as to enhance lipo-
genesis and CH production, and to increase FA β-oxidation
[90, 91]. How these changes occur and which molecular
pathways are involved remains poorly understood. Many
healthy adult mammalian tissues preferentially use exoge-
nous FAs for their needs maintaining low levels of FASN,
the enzyme catalyzing the last step of FA synthesis. Con-
versely, increased cholesterol biosynthesis and high rate of
synthesis and oxidation of endogenous FAs have been
reported in cancers from different tissues and they have
been correlated with unfavorable outcomes [83, 92, 93].
In colorectal (CR) cancer, FASN hyperactivation promotes
LD accumulation and endogenous FA β-oxidation, during
metabolic stress [86]. Moreover, the role of the lipogenic
ACS enzymes is also intensively investigated for its involve-
ment in tumor cell proliferation and tumorigenicity [94].
However, both de novo lipogenesis and upregulation of
lipolysis from intracellular storages translate in increased
FA availability for transforming cells and they seem accom-
panying the pathogenesis of cancer disease. By proteomic
analysis, Nomura and coworkers demonstrated that different
aggressive types of cancers displayed a high expression and
activity of the lipolytic MGL enzyme, compared to not
aggressive counterparts. This increased activity correlated to
higher free FA levels liberated from lipid stores and promoted
tumor aggressiveness, most likely due to the modulation of
protumorigenic lipid messengers, such as LPA and PGE2
[95]. In fact, lipids in cancer are most likely required not only
for sustaining rapid proliferation rate and a high energy con-
sumption [96] but also for stimulating signaling pathways
involved in cell survival, angiogenesis, and metastatic pro-
cesses by acting as second messengers [86, 95, 97]. Bioactive
lipids, such as phosphatidylinositol, phosphatidylserine, or
LPA, are recognized as important signaling factors able
to modulate proliferative and survival pathways, in partic-
ular the PI3K/AKT, Ras, or Wnt pathways [98].
Lipogenesis in cancer cells could have a role in making
cells less sensitive to lipid peroxidation by increasing the
saturation levels of fatty acyl chains of membrane phospho-
lipids thus altering their properties [99]. This in turn
translates, on one hand, into modulation of effectors and
pathways inside cells, such as ER stress responses [100],
and, on the other hand, into regulation of the crosstalk
between tumor cells and stroma, which may be crucial for
the progression of the transformed phenotype and for drug
resistance [83, 101, 102]. It has been demonstrated that
ovarian cancer cell growth depends on lipids derived from
adipocytes grown in coculture experiments and that such
transfer induces FA β-oxidation [103].
In order to avoid lipotoxicity due to an excess of lipids in
the cytoplasm, lipid and CH storage is ensured by LD forma-
tion. Cancer cells accumulate a larger number of LDs in their
cytoplasm when compared to normal cells [104]. For exam-
ple, breast and prostate cancers are associated to high LD
content. In breast cancer, this phenomenon has been corre-
lated with the presence of estrogen/progesterone receptors,
which are well-known modulators of cell signaling pathways
involved in cell cycle, angiogenesis, and metastasis but
also known to trigger lipogenic pathways, including the
FASN signaling [105, 106]. Treatment of breast cancer
cells with hormone medroxyprogesterone acetate results in
an increasing number and size of LDs, which are preferen-
tially enriched in saturated lipids, as revealed by Raman
spectroscopy [107]. However, estrogen receptor-negative
breast cancer cell lines also show high LD accumulation
associated with a higher lipid uptake. This may probably
confer an energetic advantage and favor the development of
a more aggressive phenotype [108]. Also, breast lipid-rich
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carcinomas are usually, but not always [109], negative for the
expression of estrogen receptors [110], thus implying more
complex levels of regulation/stimulation of lipid synthesis
and storage.
LD role in cancer is only beginning to be explored,
and recent evidence suggests that higher levels of LDs
are associated with higher tumor aggressiveness [111]
and chemotherapy resistance [112]. Moreover, some studies
report the accumulation of proteins involved in tumorigene-
sis, such as phosphatidylinositol-4,5-bisphosphate 3-kinase
(PI3K), extracellular signal-regulated kinase 1 and 2 (ERK1
and ERK2), and caveolins in LDs of different cancer cells
[113–116]. LDs also appear to be associated with inflamma-
tory responses, which can result in initiation and progression
of neoplastic processes [117, 118]. In fact, LDs have been
shown to be specialized sites involved in compartmentaliza-
tion and amplification of inflammatory mediators, such as
arachidonic acid, eicosanoids, and enzymes required for their
synthesis [115, 119]. Recently, a correlation between prosta-
glandin E2 (PGE2) synthesis and increased LD levels in
inflamed colonic tissues has been reported [120]. Further,
in an experimental work by Accioly et al. [121], the authors
showed that human colon adenocarcinoma cell lines and
colon cancer biopsies from patients present a huge increase
of LDs when compared with those from their healthy coun-
terpart. Moreover, they have also found that LDs contain
COX-2 and are structurally distinct cytoplasmic sites for
PGE2 production in an adenocarcinoma cell line [121].
Noteworthy, PGE2 is the most abundant prostaglandin
found in several human malignancies such as colon, lung,
breast, and brain [122–125] and some evidence underlies
its crucial role in promoting tumor growth [126]. It should
be also noticed that PGE2 not only promotes tumor growth
not exclusively in a paracrine way but also regulates the
interaction between tumor cells and the surrounding stromal
cells [101]. This mechanism would allow tumor cells to
escape the immune system attack, thus promoting immuno-
suppression [127]. PGE2 seems also to cause myeloid-
derived suppressor cell activation through an exosome-
dependent transport [101, 128, 129].
Penrose et al., have provided recent evidence of a link
between LD increase and epidermal growth factor receptor
(EGFR) in CR cancer. In their work, EGFR activation stimu-
lates de novo lipogenesis with consequent accumulation of
LDs expressing increased levels of PLIN2 protein in various
CR cancer cells. These effects were positively mediated by
the EGFR-induced activation of the PI3K/mTOR pathway
and of PGE2 synthesis and negatively mediated by the
inactivation (loss) of FOXO/SIRT6 tumor suppressor factors.
However, the degree of these effects varied depending on cell
line [43]. PI3K is an upstream regulator of FOXO activity;
thus, this work supports a potential regulative role of this axis
in modulating LD content in cancer cells and suggests a novel
molecular link between LDs and tumor growth. It should
be noticed that LD accumulation relies on cancer cell
metabolic status and that different genetic profiles inside
a cell population can generate heterogeneity in terms of
LD content (LDHigh and LDLow cells), defining different
adaptive responses [130, 131].
In another recent paper published by Zirath et al. [132],
the accumulation of LDs in neuroblastoma cells has been also
observed following the inhibition of the transcriptional regu-
lator, MYCN, owing to alterations of the mitochondrial
respiratory chain. Moreover, cancer cell survival by upregula-
tion of autophagy has been demonstrated in some advanced
tumors [133] and, in this respect, LDs could represent a
source of membrane lipids and energy in autophagosome
biogenesis [134, 135], thus suggesting a wider scenario for
LDs in tumorigenesis.
6. Cancer Stem Cells
The cancer stem cell hypothesis proposes that inside a tumor
mass, a subset of cells with stem-like features and named
cancer stem cells (CSCs) [136] can exist with the ability
to self-renew and, at the same time, to generate heteroge-
neous differentiated cancer cells that make up the tumor
[137]. CSCs sustain tumor growth, have the ability to
spread into other organs, and show resistance to conven-
tional therapies [138–140]. Moreover, when transplanted in
immunocompromised mice, CSCs generate new tumors,
which is consistent with the concept of heterogeneity of the
original tumor (i.e., a mixture of stem, progenitor, and
mature cells) [141–143]. This hypothesis has led to the view
that cancer is a hierarchically organized structure, with CSCs
responsible for tumor development, progression, and main-
tenance, as well as for heterogeneity [142, 144]. In this
perspective, the contribution of microenvironment/niche
cannot be overlooked. Tumor microenvironment consists
of a cellular component (muscle, immune, endothelial, and
stroma cells) and a biochemical component (growth factors
and cytokines), spatially and temporarily orchestrated, which
are believed to provide CSCs with altered stimuli able to
influence cell neoplastic growth, functions, and metabolism
[145]. CSCs have been identified in several types of cancers,
such as myeloid leukemia [138, 141], breast [146], prostate
[147], colorectal [148–150], lung [151], liver [139], mela-
noma [152, 153], and glioblastoma [154] cancers by using
different sets of makers and assays, but not without contro-
versy and limits [155]. For example, in CR cancer, CSC
populations have been identified on the basis of the markers
Lgr5 [156, 157], CD133 [148], BMI1 [158], Dclk1 [159],
CD44 [150], and ALDH-1 [160]. In breast cancer, CSCs are
characterized by high CD44 and low CD24 marker expres-
sion [146], while CD133 and CD44 are used for glioblastoma
CSCs [154, 161].
Whether CSCs derive from genetically dysregulated stem
cells (SCs), which lose the normal mechanisms of growth,
differentiation, and apoptosis control, is still under debate.
As a matter of fact, CSCs exhibit some similarities with
SCs, including self-renewal and multipotency. Nevertheless,
some evidence suggests the possibility that more differenti-
ated cancer cells might also revert to a stem-like status as
a result of a dedifferentiation process driven by genetic
alterations, thus making all tumor cells stochastically able
to have a tumor-initiating potential [143, 162]. Indeed,
both hierarchical and stochastic models could favor tumor
heterogeneity and contribute to cancer development, without
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the need for a reciprocal exclusion; cancer cell plasticity, the
effects exerted by different and dynamic microenvironments,
and the stage of cancer development could reconcile both
models [163].
In the particular case of CR cancer, it has been recently
showed that CSCs derive from normal SCs, following
the activation of specific pathways, mainly Wnt/β-catenin
[157]. On the other hand, more differentiated cells show-
ing an overactivation of Wnt signaling, induced by an
enhancement of NF-kB or by niche-secreted factors, can
also dedifferentiate towards a more primitive stage and
generate tumors [164, 165].
Compared to tumor bulk, CSCs show metabolic
alterations, which are most likely essential to sustain their
stem-like phenotype and vary depending on cancer type
[166, 167]. For example, lower mitochondrial respiration
and higher glycolytic rates have been observed in a model
of osteosarcoma [168]. On the contrary, mitochondrial
energy production by oxidative respiration rather than gly-
colysis has been reported in leukemia, glioblastoma, and
pancreatic CSCs [169–171].
De novo FA synthesis is upregulated in CSCs due to the
activation of intrinsic lipid pathways whose regulation is still
poorly understood. Together with the overexpression of
FASN even in CSCs [172], acyl-CoA synthetase ACSVL3
expression is increased in CSCs of glioblastoma neurospheres
and its regulation positively depends on the activation of
the oncogenic receptor tyrosine kinase pathway, thus cor-
relating the altered FA metabolism with CSC maintenance
and tumorigenesis [94].
Different conditions in the cancer niche, such as hypoxia/
normoxia and nutrient supply, as well as levels of growth
factors and cytokines may also act as modulators of CSC
responses [143] even in terms of accumulation of LDs, in a
continuous interplay inside the niche [173, 174] (Figure 4).
In this context, bioactive lipids and exogenous/endogenous
COX-2 and PGE2
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Figure 4: The schematic model depicts the hypothetic CSC niche (on the left) in human tumors. The main elements are summarized: (i) the
cellular components, such as CSCs, cancer cells, adipocytes, immune cells, and stroma cells [e.g., cancer-associated fibroblasts (CAFs) and
mesenchymal stem cells (MSCs)]; (ii) ECM components: collagen, laminin, and so forth; and (iii) soluble factors (growth factors,
proinflammatory cytokines, chemokines, exosomes, etc.) release from different cell types and nutrient supply from vasculature. A CSC (on
the right) shows higher amount of LDs compared with other cells. Within tumor bulk, hypoxia develops due to limited vascularization. A
continuous interplay among different factors inside the niche, including hypoxic/normoxic conditions, nutrient supply availability, the
release of soluble factors, and cell‐cell interactions contributes to determine the CSC properties and influences their metabolic plasticity, as
reviewed in [143, 163, 166, 174]. A single cancerous LD (bottom) is also schematically represented, based on [121, 178].
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FA availability may exhibit an important role in determining
CSC behavior. Indeed, it has been shown that aggressive
tumors often are surrounded by adipose tissue and home to
adipocyte-rich metastatic sites [103, 173]. Variations in
microenvironmental cues, CSC metabolic ability to adapt to
different conditions, and the cellular heterogeneity inside
the same cancer subtypes could explain the differences in
CSC metabolic reprogramming reported in literature [164].
Therefore, exploiting metabolically altered pathways of
CSCs represents an intriguing and at same time challenging
task, which might allow to identify the key factors involved
in CSC tumorigenicity. This would further help in develop-
ing novel therapeutic approaches specifically targeting this
cellular subset.
7. Lipid Droplets in Cancer Stem Cells
Until recently, few studies have focused on potential correla-
tions between lipid metabolism and stemness properties in
CSCs. However, recently, there has been a growing interest
in investigating the lipid metabolic profile in CSCs and
evidence is accumulating on the key role of lipid molecules
and consequently LDs, in CSC tumorigenicity.
Kashuba et al., in 2008, reported that overexpression of
the mitochondrial ribosomal protein S18-2 alone led to
immortalization of primary rat embryonic fibroblast induc-
ing them to express stem cell traits [175]. Later, her group
showed that the S18-2-immortalized cells underwent cell
transformation and gave rise to tumors in SCID mice [176].
These cells showed induction of stem cell maintenance
markers, such as Sox2 and Oct4, and the activation of some
cellular pathways, such as cell proliferation, oxidative phos-
phorylation, and cellular respiration. Importantly, the most
tumorigenic S18-2 clones had the largest amount of LDs
when compared to the other clones, suggesting that the
LD expression is functionally linked with increased cancer
metabolism, stemness, and tumorigenicity [176].
As in more differentiated breast cancer cells, FASN
expression appears upregulated in breast CSCs [177], while
in ovarian ALDH+/CD133+ CSCs (OCSCs), a higher grade
of unsaturated lipids has been found inside LDs, compared
to non CSCs, by using Raman microspectroscopy and mass
spectrometry [178]. This evidence has been associated to a
higher expression of stearoyl-CoA desaturase-1 (SCD1),
which catalyzes the synthesis of monounsaturated FAs. Thus,
the high SCD1 levels and abundance of LDs enriched in
unsaturated FAs would represent an altered metabolic
feature of OCSCs and would have a functional role in the
stemness maintenance, both in vitro and in vivo. The authors
also provide evidence that the SCD1 activity and the nuclear
factor NF-kB (NF-kB) pathway are regulated by a positive
feedback loop [178]. However, the molecular mechanisms
underlying this interaction are unknown.
It has been established that the hyperactivation of NF-kB
signaling induces the expression of stemness-associated
genes and of inflammatory genes in CSCs, thus suggesting
a link between inflammation and tumorigenesis [179].
Recent observations pointed out to saturated FAs as poten-
tial factors stimulating inflammatory responses [180], with
NF-kB acting as a main player. Moreover, among other
factors, NF-kB activation is also mediated by the Toll-like
receptor (TLR) family, expressed in different types of cancer
[181, 182]. Interestingly, a recent paper demonstrated the
ability of saturated FAs to activate TLR-2 and TLR-4 signal-
ing pathways [183]. TLRs trigger inflammatory responses
through the activation of transcription factors, including
NF-kB, which can result in promoting cancer cell prolifera-
tion, invasion, and tumorigenesis [184]. For example, it has
been shown that the TLRs/NF-kB pathway supports ovarian
CSC self-renewal [185]. In light of these results, CSCs, LDs,
and NF-kB signaling might be much more tightly connected
than so far investigated.
Notably, in Li et al.’s work, the upregulation of SCD1 in
CSCs is associated with greater tumorigenicity and poor
prognosis [178]. In a recently published paper, Noto et al.
have shown that lung cancer stem cell spheroids display an
increased amount of unsaturated FAs dependent upon the
SCD1 activity. This latter induces the activation of Wnt/
β-catenin signaling, and this axis, in turn, regulates the
nuclear localization (activation) of YAP/TAZ, effectors
involved in the Hippo pathway (Figure 5). Such a correla-
tion was also associated with poor prognosis in test sam-
ples of human lung adenocarcinoma [186]. Actually,
YAP/TAZ are inducers of stem cell proliferation and sur-
vival and, in several cancers, their expression sustains
tumor growth and invasion [187, 188]. Also, YAP/TAZ
activity seems to be modulated by metabolic pathways,
including glycolysis and mevalonate pathway [189]. Thus,
Noto et al.’s study provides evidence that the expression
of SCD1 enzyme, from which at least in part depends a
specific lipid composition of LDs, promotes cancer stem-
ness, and describes a possible link between dysregulated
lipid metabolism and YAP/TAZ oncogenic activity.
The LD accumulation has been also observed in circu-
lating tumor cells (CTCs). Lipid-rich CTCs were detected
in the peripheral blood of patients with metastatic prostate
or lung cancers by using Raman spectroscopy. This sup-
ports the idea that intracellular lipids could be involved
in cancer aggressiveness and that LDs could be used as a
potential biomarker [81, 190].
Recently, a paper published by our group [131] demon-
strated a higher accumulation of LDs in different patient-
derived CR-CSCs compared to their nonstem counterparts.
By measurements performed with different techniques,
including Raman microspectroscopy, it has been shown that
the traditional CR-CSC markers (CD133 and Wnt/β-catenin
pathway activity) directly correlate with the cell fraction
having the highest LD content (CR-CSC LDHigh). Further-
more, an in vivo test demonstrated that most of the
tumorigenic potential is restricted to the CR-CSC LDHigh
subpopulation. These results suggest that LDs might be
used as a functional marker for CR-CSC identification and
that Raman microspectroscopy holds a great potential for
translational research on cancer stem cells. Raman micro-
spectroscopy [191] is indeed a label-free technique based on
vibrational spectroscopy; that is, imaging of samples is
performed by probing, with subcellular resolution, and by
optical means and molecular vibrations, which are specific
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to chemical bonds and structures of the molecules. This
imaging method, which uses sample chemical composition
as a contrast mechanism, is particularly suited to probe
lipid biomolecules, which has been recently exploited to
uniquely obtain quantitative chemical information on LDs
(e.g., lipid saturation degree and cholesterol content) in live
cells [178, 192].
A similar correlation between LDs, CD133, and Wnt/
β-catenin has been proved in human metastatic melanoma
cells, where the downregulation of CD133 resulted in
reduced Wnt/β-catenin pathway signaling and decreased
levels of LDs, as observed by Raman microspectroscopy,
with a consequent reduced metastatic potential [193, 194].
Altogether, these findings corroborate the idea that
LD accumulation and profile could have an important
role on tumorigenic properties of CSCs and could repre-
sent a potential novel target for cancer prevention or
treatment options.
8. Conclusions and Future Perspectives
Metabolic reprogramming in tumor cells is now considered
one of the hallmarks of cancer [84], and it includes not only
the increase of glucose uptake resulting in favoring glycolysis
but also the upregulation of glutamine and lipid metabolism
[195–197], aiming at sustaining rapid cell proliferation
and biomass production. Increased de novo FA synthesis
is a feature of many cancer cells and results in increased
accumulation of LDs [115].
Different classes of drugs have been demonstrated to
inhibit diverse lipid pathways, both in a direct and indi-
rect way although no specific LD inhibitors have been
described so far; examples of them are nonsteroidal anti-
inflammatory drugs [198, 199] and statins [200]. Even if
the mechanism of action of these drugs is not yet completely
understood, they have exhibited promising results in the
prevention of the CR cancer, suggesting a pivotal role for
NF-휅B
Proinflammatory
responses
Saturated FAs
SCD1
Unsaturated FAs
Acetyl-CoA
FASN
Li
po
ly
sis
Bioactive lipids
membrane synthesis
Wnt/훽-catenin
signaling
YAP/TAZ
activation
External stimuli (infections,
cytokines, lipids, etc.)
ER
Nucleus
CSC proliferation
Invasiveness
Tumorigenesis
LD
Figure 5: Hypothetical model of NF-kB/SCD1 pathway based on [177, 185]. Activated NF-kB pathway stimulates SCD1 upregulation,
which could modulate several pathways (such as Wnt/β-catenin and YAP/TAZ signalings) resulting in CSC proliferation, cancer
invasiveness, and tumorigenesis.
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the LDs in CR-CSCs. Moreover, very recent results are indi-
cating an even tighter connection between lipid metabolism
and stemness [131, 178, 201, 202].
While it is becoming clear that LDs are involved in
multiple cellular processes, their role in cancer and cancer
stem cells needs further investigations. Research has made
remarkable progresses in this field, but many questions
regarding the LD biology still remain unanswered. In this
regard, the questions arise as to whether differences in LD
composition between healthy and cancer cells and among
different tumors exists. Moreover, which functional roles
have LDs in tumorigenesis and which advantages do they
confer to CSCs in terms of tumorigenicity? Whether,
throughout tumor development, CSC pool maintains itself
uniform and stable or different CSC subclones originate with
different stemness features at different stages is another
open question. Accordingly, do LD expression levels change
dynamically during cancer progression and, if so, how the
tumor microenvironment may influence this expression?
Investigating the modulation of LD expression and under-
standing their functional role will be of pivotal importance
also for developing new potential strategies and targets
for diagnosis and therapeutic purposes. Interdisciplinary
approaches bringing together techniques like mass spectrom-
etry, nuclear magnetic resonance, and Raman spectroscopies
will allow performing new and deeper investigations of lipid
phenotype, fatty acid composition, and spatial distribution of
lipids and LDs inside tumors. Noticeably, Raman microspec-
troscopy adds to this set of techniques its unique capability to
perform chemical imaging with high spatial resolution in live
cells and without addition of any exogenous tag, as such
being suitable even for in vivo applications. Moreover, it
has been recently benefited by a quantum leap in technical
development, through so-called “coherent Raman”methods,
which have paved the way to quantitative investigations of
lipid dysregulation in live cancer cells with spatial and
temporal details inaccessible to other methods [203].
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